Evidence map›Paper›PMID 40776771›Full record

ReviewNanomedicine (London, England)2025

Emerging nanoparticles that target and eliminate cancer stem cells.

Zitao Fan, Baizhu Chen, Xiangliang Yang, Zifu Li

Abstract readReview
In one paragraph

Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zitao FanDepartment of Nanomedicine and Biopharmaceuticals, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, P. R. China.
Baizhu ChenSchool of Biomedical Engineering, Shenzhen Campus of Sun Yat-Sen University, Shenzhen, Guangdong, China.
Xiangliang YangDepartment of Nanomedicine and Biopharmaceuticals, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, P. R. China.
Zifu LiDepartment of Nanomedicine and Biopharmaceuticals, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, P. R. China.

Funding

HCP Program for HUST, and the Opening fund of Hubei Key Laboratory of Bioinorganic Chemistry & Materia MedicaNational Key Research and Development Program of ChinaNational Natural Science Foundation of ChinaProgram for HUST Academic Frontier Youth TeamScientific Research Foundation of HUST
6 · The paper itself

Abstract

Cancer stem cells (CSCs), a distinct subpopulation within tumors possessing self-renewal and multilineage differentiation capacities, represent the pivotal drivers of therapeutic resistance, tumor recurrence, and metastatic dissemination. The inherent heterogeneity and drug resilience of CSCs render conventional chemotherapy and radiotherapy largely ineffective against this population despite their ability to eliminate bulk tumor cells, ultimately limiting treatment outcomes. In recent years, nanoparticles (NPs) have emerged as promising therapeutic platforms for CSCs-targeted intervention due to their unique physicochemical properties and multifunctional capabilities. This review systematically summarizes recent advances in utilizing organic (liposomes, polymeric nanoparticles), inorganic (gold, silica), and biologically derived (extracellular vesicles, cell membrane-coated NPs) NPs for CSCs eradication. These nanoplatforms achieve active CSCs targeting and elimination through surface modification with CSCs-specific markers, pathway-targeting molecules, or regulators of CSCs biological properties. Although significant progress has been made in nanoparticle-mediated anti-CSCs therapy, critical challenges remain in targeting efficiency, scalable manufacturing, and comprehensive safety evaluation. The continued evolution of drug delivery systems (DDSs) coupled with future breakthroughs in drug delivery vehicles will undoubtedly lead to greater advances in CSCs-targeted DDSs.

Indexed as

Antineoplastic AgentsDrug Delivery SystemsNanoparticlesNeoplasmsNeoplastic Stem CellsAnimalsHumansAntineoplastic AgentsCancer stem cellsheterogeneitynano drug delivery systemsnanomedicinetargeted therapy strategies

Identifiers

PMID40776771
PMCPMC12413036

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.